Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma

Carfilzomib, a second-generation irreversible proteasome inhibitor, is currently considered the preferred therapy for relapsed and refractory multiple myeloma. There are several cardiovascular adverse effects described with carfilzomib chemotherapy most commonly being hypertension, dyspnea and decre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Pankaj, Thanendrarajan, Sharmilan, Lopez-Candales, Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104323/
https://www.ncbi.nlm.nih.gov/pubmed/33986932
http://dx.doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_107_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104323/
https://www.ncbi.nlm.nih.gov/pubmed/33986932
http://dx.doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_107_20

Ejemplares similares